Online inquiry

IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15009MR)

This product GTTS-WQ15009MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15009MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12512MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ14136MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ1236MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ8396MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ11624MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ4523MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ2840MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ8180MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HL161
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW